ArticleScientific reports2025
Synergistic effect of Agrococcus and Rossellomorea Marisflavi species assisted probiotic functional feed on Vibrio affected Nile tilapia fish.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-organ histological assessment of Agrococcus sp. RKDAS_1 reveals tissue-level biocompatibility in Oreochromis niloticus.Journal of molecular histology · 2026Review
- Isolation and characterization of indigenous probiotic bacteria from wild Nile tilapia (Veterinary world · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probiotics offer significant health advantages as they enter the digestive system via diet or water intake, playing a crucial role in enhancing immunity, growth, gastrointestinal microbiota, and feed attribute. The main objective of study was to focus on the impact of probiotic functional feed (PFF) on Nile tilapia (Oreochromis niloticus) exposed to challenges from Vibrio harveyi and Vibrio parahaemolyticus. The investigation aims to analyze the genes linked to immunity, hemato-biochemical indices, and the immunological response in tilapia. PFF is a vital component of fish feed production, providing suitable nutrition for various ages and stages to promote healthy growth. The study comprises four treatments: CPF-1 (control group, diet included solely of basal fish feed), the 20% of PFF2 (Rossellomorea marisflavi spp. (DAS-SCF02-1 × 104), PFF3 (Agrococcus spp. (RKDAS1-1 × 106), and PFF4- (DAS-SCF02-1 × 104 + RKDAS1 (1 × 107). A total of 150 Nile tilapia juveniles, weighing 2.56 ± 1.26 g, were administered PFF in triplicates. Significant improvements were observed in hematological indices, encompassing white blood cells (WBC), hemoglobin (Hb), red blood cells (RBC), hematocrit (Htc), and blood performance (BP) in probiotic-treated groups compared to control. Biochemical analysis revealed lower levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in fish fed with probiotics, accompanied by increased total protein, albumin, and globulin levels. Furthermore, probiotic-fed fish exhibited heightened blood glucose, total cholesterol, and triglyceride levels. Immunological assessments demonstrated increased lysozyme activity, intracellular superoxide anion production, reactive nitrogen species synthesis, and myeloperoxidase activity in probiotic-fed groups. Immune gene expression analysis revealed up-regulation of stress response, cytokine signaling, and immune defense-related genes (HSP70, IL-1β, I C3, IFN-α, IFN-γ, GF1, GH, IL-1, and Lyz). In a Vibrio challenge study, probiotic-fed fish exhibited improved survival rates, underscoring the protective effects of probiotics against bacterial infections. Overall, this research underscores the multifaceted benefits of probiotic supplementation in enhancing the health and immunity of tilapia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.